CFTR and cystic fibrosis: With the FDA approval of using CFTR modulator Trikafta (elexacaftor, tezacaftor, and ivacaftor as a combination drug) for treatment of CF in patients >=12 years old, there are finally effective treatment options available for most CFTR mutation types (Voelker, 2019).